LEPTON and TAmiRNA collaborate on microRNA immune therapy discovery
Lepton Pharmaceuticals LTD (Lepton), a biopharmaceutical company, focused on discovery and development of novel treatments for unmet medical needs, exploiting the subtle silencing of coding RNA expression by noncoding RNA molecules microRNA (miRNA) and small interfering RNA, and TAmiRNA GmbH, a research and development company specialized in the discovery and validation of microRNA biomarkers to improve patients’ life, announce the reinforcement of their collaboration by signing a second agreement to discover the epigenetic pathways that affect the activity of microRNAs thereby improving genetically modified immune cells therapy. Lepton together with Freiburg University is developing a technology (the Castling Technology) for enhancement of immune cells (T-cells or CAR T-cells, B-cells, natural killer (NK) cells, T-regulatory cells, macrophages, stem cells [...]